Prostate cancer is the most common cancer diagnosed in men and the second leading cause of death in male cancer patients. The WHO suggests that cobalt is involved in the carcinogenesis of prostate cancer. There are, however, no studies associating cobalt levels and prostate cancer patient survival. In this study, 261 Polish prostate cancer (n= 261) patients were recruited into a prospective cohort between 2009 and 2015. Serum cobalt levels were measured using ICP-MS after prostate cancer diagnosis and before treatment. All study participants were assigned into quartiles (QI-QIV) based on the distribution of serum cobalt levels among censored patients. Univariable and multivariable COX regression models were used to calculate hazard ratios (HRs) for each serum cobalt level quartile. We found a significant relationship between high serum cobalt levels and poor prostate cancer patient total survival (HR = 2.60; 95% CI: 1.17–5.82;p= 0.02). In relation to prostate cancer patients who died as a result of other non-cancer causes, the association with high levels of cobalt was even stronger (HR = 3.67; 95% CI: 1.03–13.00;p= 0.04). The impact of high serum cobalt levels on overall survival of prostate cancer-specific-related deaths was not statistically significant.
前列腺癌是男性最常见的恶性肿瘤，也是男性癌症患者第二大死亡原因。世界卫生组织指出钴元素参与前列腺癌的致癌过程。然而目前尚无研究探讨钴水平与前列腺癌患者生存期的关联。本研究于2009年至2015年间招募261名波兰前列腺癌患者建立前瞻性队列，在确诊后治疗前采用电感耦合等离子体质谱法检测血清钴水平。根据删失患者的血清钴水平分布将所有研究对象分为四个等级（QI-QIV）。通过单变量和多变量COX回归模型计算各血清钴水平等级的风险比。研究发现高血清钴水平与前列腺癌患者总生存期不良存在显著关联（HR=2.60；95%CI：1.17-5.82；p=0.02）。在因其他非癌症原因死亡的患者中，高钴水平的关联性更为显著（HR=3.67；95%CI：1.03-13.00；p=0.04）。高血清钴水平对前列腺癌特异性死亡总生存期的影响未达到统计学意义。
Cobalt Serum Level as a Biomarker of Cause-Specific Survival among Prostate Cancer Patients
肿瘤(癌症)患者之家